Trillium Therapeutics Inc. ("Trillium" or the "Company") announced that it has agreed to sell 2,297,794 of its common shares at a price of $10.88 per share to Pfizer Inc. for gross proceeds of $25.0 million (the "Transaction"). In addition, Dr. Jeff Settleman, Senior Vice President and Chief Scientific Officer, Oncology, Worldwide Research, Development & Medical, Pfizer, has agreed to join Trillium's Scientific Advisory Board (SAB), once formed. It is anticipated that the SAB will be announced later this year. The SAB will work closely with Trillium's senior management team to guide the Company's scientific and clinical strategic priorities.